[go: up one dir, main page]

AU2000255635A1 - A process for the preparation of anti-pschotic 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl -6,7,8,9-tetrahydro-2-methyl-4h-pyridol(1,2,-a)pyrimidin-4- one - Google Patents

A process for the preparation of anti-pschotic 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl -6,7,8,9-tetrahydro-2-methyl-4h-pyridol(1,2,-a)pyrimidin-4- one

Info

Publication number
AU2000255635A1
AU2000255635A1 AU2000255635A AU5563500A AU2000255635A1 AU 2000255635 A1 AU2000255635 A1 AU 2000255635A1 AU 2000255635 A AU2000255635 A AU 2000255635A AU 5563500 A AU5563500 A AU 5563500A AU 2000255635 A1 AU2000255635 A1 AU 2000255635A1
Authority
AU
Australia
Prior art keywords
pyrimidin
methyl
tetrahydro
preparation
piperidinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2000255635A
Inventor
Tarur Venkatasubramanian Radhakrishnan
Dhananjay Govind Sathe
Chandrakant Vasantrao Suryavanshi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RPG Life Sciences Ltd
Original Assignee
RPG Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RPG Life Sciences Ltd filed Critical RPG Life Sciences Ltd
Publication of AU2000255635A1 publication Critical patent/AU2000255635A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A process for the preparation of 3-substituted ethyl-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2,-a]pyrimidin-4-one of the formula IIB: where X may be halo, acyloxy, or sulfonyloxy such as tosyloxy or mesyloxy, an intermediate in the synthesis of the anti-psychotic risperidone. The process comprises hydrogenation of 3-substituted ethyl-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one in aqueous inorganic acid medium at atmospheric to 60 psi at 0-100° C. in the presence of a metal catalyst and the product is isolated. A process for the preparation of risperidone of the formula I: comprising condensation of 3-substituted ethyl-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2,-a]pyrimidin-4-one with 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole in water in the presence of an inorganic base at 25-100° C. and the product is isolated.
AU2000255635A 2000-05-05 2000-05-05 A process for the preparation of anti-pschotic 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl -6,7,8,9-tetrahydro-2-methyl-4h-pyridol(1,2,-a)pyrimidin-4- one Abandoned AU2000255635A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2000/000053 WO2001085731A1 (en) 2000-05-05 2000-05-05 A PROCESS FOR THE PREPARATION OF ANTI-PSCHOTIC 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2,-a]pyrimidin-4-one

Publications (1)

Publication Number Publication Date
AU2000255635A1 true AU2000255635A1 (en) 2001-11-20

Family

ID=11076248

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2000255635A Abandoned AU2000255635A1 (en) 2000-05-05 2000-05-05 A process for the preparation of anti-pschotic 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl -6,7,8,9-tetrahydro-2-methyl-4h-pyridol(1,2,-a)pyrimidin-4- one

Country Status (7)

Country Link
US (1) US6897308B1 (en)
EP (1) EP1280804B1 (en)
AT (1) ATE264329T1 (en)
AU (1) AU2000255635A1 (en)
CZ (1) CZ295402B6 (en)
DE (1) DE60009959T2 (en)
WO (1) WO2001085731A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0302874A2 (en) 2000-08-14 2003-12-29 Teva Pharmaceutical Industries Ltd. Process for preparation of risperidone
HU227118B1 (en) * 2001-11-13 2010-07-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of 3-{2-[4-(6-fluoro-1,2-benzizoxazol-3-yl)-1-piperidinyl]-ethyl}-6,7,8,9-tetrahydro-2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one
ES2197801B1 (en) 2002-03-05 2005-03-16 Ferrer Internacional,S.A PROCEDURE FOR OBTAINING THE 3- (2- (4- (6-FLUORO-BENZO (D) ISOXAZOL-3-IL) PIPERIDIN-1-IL) -ETIL) -2-METHYL-6,7,8,9- TETRAHIDRO-4H-PIRIDO- (1,2-A) PIRIMIDIN-4-ONA.
KR20040025224A (en) * 2002-09-18 2004-03-24 주식회사 대웅 2-(2-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-3-yl)acetaldehyde and preparation process of the same
KR20040034996A (en) 2002-10-18 2004-04-29 한미약품 주식회사 Improved method for the preparation of risperidone
EP1560814A1 (en) 2002-11-13 2005-08-10 Synthon B.V. Process for making risperidone and intermediates therefor
AU2004276092A1 (en) * 2003-09-26 2005-04-07 Jubilant Organosys Ltd. Process for the preparation of risperidone
HUP0401379A3 (en) * 2004-07-08 2006-04-28 Richter Gedeon Vegyeszet Process for the preparation of risperidon
HUP0402163A2 (en) * 2004-10-25 2006-05-29 Richter Gedeon Vegyeszet Process for the preparation of risperidone
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
WO2007093870A2 (en) * 2006-02-15 2007-08-23 Orchid Chemicals & Pharmaceuticals Limited A process for the preparation of risperidone
DE202007018473U1 (en) 2006-08-14 2008-08-07 Teva Pharmaceutical Industries Ltd. 9-hydroxy risperidone (paliperidone)
US7820816B2 (en) * 2006-08-23 2010-10-26 Teva Pharmaceutical Industries Ltd. Process for the synthesis of CMHTP and intermediates thereof
WO2008153611A2 (en) 2007-05-25 2008-12-18 Qlt Usa, Inc. Sustained delivery formulations of risperidone compounds
CN101353347B (en) * 2007-07-26 2011-06-01 齐鲁制药有限公司 Preparation of risperidone
EP2285804A4 (en) * 2008-04-21 2011-09-14 Glenmark Generics Ltd A process for the preparation of paliperidone intermediates

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4355037A (en) 1981-11-12 1982-10-19 Hoechst-Roussel Pharmaceuticals 3-(4-Piperidyl)-1,2-benzisoxales
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US4957916A (en) 1988-08-05 1990-09-18 Janssen Pharmaceutica N.V. Antipsychotic 3-piperazinylbenzazole derivatives
US5015740A (en) 1988-08-05 1991-05-14 Janssen Pharmaceutica N.V. Antipsychotic 3-piperazinylbenzazole derivatives
ES2050069B1 (en) * 1992-07-10 1994-12-16 Vita Invest Sa PROCEDURE FOR OBTAINING 3- (2- (4- (6-FLUORO-1,2-BENZISOXAZOL-3-IL) PIPERIDINO) ETIL) -2-METHYL-6,7,8,9-TETRAHIDRO-4H-PIRIDO (1,2-A) PIRIMIDIN-4-ONA.
ES2074966B1 (en) * 1994-02-11 1996-06-16 Vita Invest Sa PROCEDURE FOR OBTAINING 3- (2- (4- (6-FLUORO-BENZO (D) ISOXAZOL-3-IL) PIPERIDIN-1-IL) -ETIL) -2-METHYL-6,7,8,9- TETRAHIDRO-4H-PIRIDO- (1,2-A) PIRIMIDIN-4-ONA.

Also Published As

Publication number Publication date
DE60009959D1 (en) 2004-05-19
WO2001085731A1 (en) 2001-11-15
DE60009959T2 (en) 2005-03-31
CZ295402B6 (en) 2005-08-17
ATE264329T1 (en) 2004-04-15
EP1280804A1 (en) 2003-02-05
US6897308B1 (en) 2005-05-24
EP1280804B1 (en) 2004-04-14
CZ20023666A3 (en) 2003-02-12

Similar Documents

Publication Publication Date Title
AU2000255635A1 (en) A process for the preparation of anti-pschotic 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl -6,7,8,9-tetrahydro-2-methyl-4h-pyridol(1,2,-a)pyrimidin-4- one
US8829006B2 (en) Compounds
US6979686B1 (en) Substituted pyrazoles as p38 kinase inhibitors
US9145410B2 (en) Pyrazolopyridines and analogs thereof
US9963462B2 (en) Sepiapterin reductase inhibitors
US7544697B2 (en) Pyrazolopyridines and analogs thereof
US7419988B2 (en) Azaindole inhibitors of aurora kinases
JP5784620B2 (en) Imidazole derivatives as casein kinase inhibitors
US8686143B2 (en) Compounds useful as inhibitors of Janus kinases
KR101590236B1 (en) Novel fused pyridine compounds as casein kinase inhibitors
AU2005280740B2 (en) Pyrrolo[2,3-c]pyridine derivatives and processes for the preparation thereof
CA1324131C (en) 2-(heterocyclylalkyl)imidazopyridines
WO1992022551A1 (en) IMIDAZO[2,1-b][3]BENZAZEPINE DERIVATIVES, COMPOSITIONS AND METHOD OF USE
RS20080371A (en) Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
WO2003053975A1 (en) Pyrazolopyrimidinone derivatives having pde7-inhibitory activity
EP1749004A1 (en) Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents
FI90238B (en) Process for the preparation of antipsychotic 3-piperazinylbenzazole derivatives
WO1992006086A1 (en) Novel 4-piperidinylcarbonyl derivatives
CN105814035A (en) Inhibitors of bruton's tyrosine kinase
HK1226070B (en) Inhibitors of bruton’s tyrosine kinase
ES2050069A1 (en) Prepn of anti-psychotic pyrimidinone - which is 3-(2-(4-(6-fluoro- 1,2-benzisoxazol 3-yl)piperidino) ethyl)-2-methyl- 6,7,8,9-tetra- hydro-4H-pyrido (1,2-a) pyrimidin-4-one
CZ32995A3 (en) PROCESS FOR PREPARING 3-(2-/4-(6-FLUOROBENZO/ISOXAZOL-3-YL)PIPERIDIN-1-YL/ETHYL)-2-METHYL-6,7,8, 9-TETRAHYDRO-4H-PYRIDO/1,2-a/PYRIMIDIN-4-ONE
US20100130740A1 (en) Process for preparation of risperidone
BR0308139A (en) Process for preparing 3- (2- (4- (6-fluorbenzo (d) isoxazol-3-yl) piperidin-1-yl) ethyl) -2-methyl-6,7,8,9-tetrahydro 4h-pyrido- (1,2-a) -pyrimidin-4-o in
WO2006005974A8 (en) A process for the preparation of risperidone